학술논문
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non–Small-Cell Lung Cancer
Document Type
Article
Author
Source
In Clinical Lung Cancer July 2020 21(4):e286-e293
Subject
Language
ISSN
1525-7304
Abstract
Micro-Abstract Despite the advancement of immunotherapy in advanced non–small-cell lung cancer, patients with poor performance status (PS) have been excluded from clinical trials and it is unknown if the benefit exists in this cohort. Our retrospective study showed that immunotherapy is an active regimen in patients with poor PS, however, inferior survival outcomes were noted when compared to medically fit patients.